MedTrace Logo

Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease

NCT05762952 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-08-22

No results posted yet for this study

Summary

The goal of this clinical trial is to test the effects of a drug (in the drug class called sodium-glucose cotransporter 2 inhibitors) in women who have symptoms of ischemic heart disease. The main questions the study aims to answer are:

Does blood flow in the heart improve with study drug?

Participants will be randomly assigned to a 12-week course of the study drug, dapagliflozin 10mg, or placebo. Blood flow in the heart will be assessed using stress cardiac magnetic resonance imaging at baseline and 12 weeks. The researchers will compare the results from the two groups.

Conditions

  • Myocardial Ischemia

Interventions

DRUG

Dapagliflozin 10mg Tab

Once daily oral dapagliflozin 10mg

DRUG

Placebo

Placebo capsules formulated by pharmacy to be indistinguishable from active drug

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Patricia Rodriguez-Lozano, MD · University of Virginia Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-06
Primary Completion
2025-08-05
Completion
2026-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05762952 on ClinicalTrials.gov